Isolation of novel EGFR-specific VHH domains

Journal of Biomolecular Screening

Volumn 14, Issue 1, 2009, Pages 77-85

  Gottlin, Elizabeth B ^a   Guan, Xiangrong ^a   Pegram, Charles ^a   Cannedy, Allen ^b   Campa, Michael J ^a   Patz Jr , Edward F ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b NORTH CAROLINA STATE UNIVERSITY   (United States)

Author keywords

Cancer; EGFR; Phage display; VHH domains

Indexed keywords

CELL RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; MONOCLONAL ANTIBODY; RECOMBINANT PROTEIN; TUMOR MARKER;

ANIMAL CELL; ANTIBODY SPECIFICITY; ARTICLE; BINDING AFFINITY; BINDING KINETICS; BIOLOGICAL ACTIVITY; CANCER DIAGNOSIS; CELL LYSATE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; GENE MUTATION; GENE OVEREXPRESSION; HEAVY CHAIN; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOPRECIPITATION; MOLECULAR PROBE; MOLECULAR WEIGHT; NEOPLASM; NONHUMAN; PHAGE DISPLAY; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DOMAIN; SURFACE PLASMON RESONANCE; THERMODYNAMICS; TUMOR CELL; TUMOR CELL LINE;

AMINO ACID SEQUENCE; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODY SPECIFICITY; CELL LINE; CROSS REACTIONS; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; IMMUNOPRECIPITATION; KINETICS; MICE; MOLECULAR SEQUENCE DATA; PEPTIDE FRAGMENTS; PHYLOGENY; RECEPTOR, EPIDERMAL GROWTH FACTOR; SEQUENCE ALIGNMENT; SURFACE PLASMON RESONANCE; THERMODYNAMICS;

LAMA (MAMMAL);

EID: 58849114161     PISSN: 10870571     EISSN: 1552454X     Source Type: Journal    
DOI: 10.1177/1087057108327064     Document Type: Article

References (42)

1. Ullrich A., Coussens L., Hayflick JS, Dull TJ, Gray A., Tam AW,, et al. Human epidermal growth factor receptor cDNA sequence and aberrant expression of the amplified gene in A431 epidermoid carcinoma cells. Nature 1984 ; 309: 418-425.
2. Schlessinger J.: Ligand-induced, receptor-mediated dimerization and activation of EGF receptor. Cell 2002 ; 110: 669-672.
3. Fischer OM, Hart S., Gschwind A., Ullrich A.: EGFR signal transactivation in cancer cells. Biochem Soc Trans 2003 ; 31: 1203-1208.
4. Dikic I.: Mechanisms controlling EGF receptor endocytosis and degradation. Biochem Soc Trans 2003 ; 31: 1178-1181.
5. Lynch TJ, Bell DW, Sordella R., Gurubhagavatula S., Okimoto RA, Brannigan BW,, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004 ; 350: 2129-2139.
6. Hirsch FR, Scagliotti GV, Langer CJ, Varella-Garcia M., Franklin WA: Epidermal growth factor family of receptors in preneoplasia and lung cancer: perspectives for targeted therapies. Lung Cancer 2003 ; 41 (suppl 1). S29 - S42.
7. Kuan CT, Wikstrand CJ, Bigner DD: EGFRvIII as a promising target for antibody-based brain tumor therapy. Brain Tumor Pathol 2000 ; 17: 71-78.
8. Kim H., Muller WJ: The role of the epidermal growth factor receptor family in mammary tumorigenesis and metastasis. Exp Cell Res 1999 ; 253: 78-87.
9. Maihle NJ, Baron AT, Barrette BA, Boardman CH, Christensen TA, Cora EW,, et al. EGF/ErbB receptor family in ovarian cancer. Cancer Treat Res 2002 ; 107: 247-258.
10. Lorenzo GD, Bianco R., Tortora G., Ciardiello F.: Involvement of growth factor receptors of the epidermal growth factor receptor family in prostate cancer development and progression to androgen independence. Clin Prostate Cancer 2003 ; 2: 50-57.
11. Meert AP, Verdebout J-M., Martin B., Ninane V., Feoli F., Sculier J-P.: Epidermal growth factor receptor expression in pre-invasive and early invasive bronchial lesions. Eur Respir J 2003 ; 21: 611-615.
12. Piyathilake CJ, Frost AR, Manne U., Weiss H., Bell WC, Heimburger D.,, et al. Differential expression of growth factors in squamous cell carcinoma and precancerous lesions of the lung. Clin Cancer Res 2002 ; 8: 734-744.
13. Selvaggi G., Novello S., Torri V., Leonardo E., De Giuli P., Borasio P.,, et al. Epidermal growth factor receptor overexpression correlates with a poor prognosis in completely resected non-small-cell lung cancer. Ann Oncol 2004 ; 15: 28-32.
14. Garcia de Palazzo IE, Adams GP, Sundareshan P., Wong AJ, Testa JR, Bigner DD,, et al. Expression of mutated epidermal growth factor receptor by non-small cell lung carcinomas. Cancer Res 1993 ; 53: 3217-3220.
15. Okamoto I., Kenyon LC, Emlet DR, Mori T., Sasaki J., Hirosako S.,, et al. Expression of constitutively activated EGFRvIII in non-small cell lung cancer. Cancer Sci 2003 ; 94: 50-56.
16. Wikstrand CJ, Hale LP, Batra SK, Hill ML, Humphrey PA, Kurpad SN,, et al. Monoclonal antibodies against EGFRvIII are tumor specific and react with breast and lung carcinomas and malignant gliomas. Cancer Res 1995 ; 55: 3140-3148.
17. Pedersen MW, Meltorn M., Damstrup L., Poulsen HS: The type III epidermal growth factor receptor mutation: biological significance and potential target for anti-cancer therapy. Ann Oncol 2001 ; 12: 745-760.
18. Padrón D., Sato M., Shay JW, Gazdar AF, Minna JD, Roth MG: Epidermal growth factor receptors with tyrosine kinase domain mutations exhibit reduced Cbl association, poor ubiquitylation, and down-regulation but are efficiently internalized. Cancer Res 2007 ; 67: 7695-7702.
19. Wong SF: Cetuximab: an epidermal growth factor receptor monoclonal antibody for the treatment of colorectal cancer. Clin Ther 2005 ; 27: 684-694.
20. Socinski MA: Antibodies to the epidermal growth factor receptor in non small cell lung cancer: current status of matuzumab and panitumumab. Clin Cancer Res 2007 ; 13: s4597 - s4601.
21. O'Donovan N., Crown J.: EGFR and HER-2 antagonists in breast cancer. Anticancer Res 2007 ; 27: 1285-1294.
22. Hamers-Casterman C., Atarhouch T., Muyldermans S., Robinson G., Hamers C., Songa EB,, et al. Naturally occurring antibodies devoid of light chains. Nature 1993 ; 363: 446-448.
23. Sheriff S., Constantine KL: Redefining the minimal antigen-binding fragment. Nat Struct Biol 1996 ; 3: 733-736.
24. Dumoulin M., Conrath K., Van Meirhaeghe A., Meersman F., Heremans K., Frenken LGJ,, et al. Single-domain antibody fragments with high conformational stability. Protein Sci 2002 ; 11: 500-515.
25. Cortez-Retamozo V., Lauwereys M., Hassanzadeh Gh G., Gobert M., Conrath K., Muyldermans S.,, et al. Efficient tumor targeting by single-domain antibody fragments of camels. Int J Cancer 2002 ; 98: 456-462.
26. Muruganandam A., Tanha J., Narang S., Stanimirovic D. Selection of phage-displayed llama single-domain antibodies that transmigrate across human blood-brain barrier endothelium. Faseb J 2002 ; 16: 240-242.
27. Roovers RC, Laeremans T., Huang L., De Taeye S., Verkleij AJ, Revets H.,, et al. Efficient inhibition of EGFR signaling and of tumour growth by antagonistic anti-EFGR Nanobodies. Cancer Immunol Immunother 2007 ; 56: 303-317.
28. Batra SK, Castelino-Prabhu S., Wikstrand CJ, Zhu X., Humphrey PA, Friedman HS,, et al. Epidermal growth factor ligand-independent, unregulated, cell-transforming potential of a naturally occurring human mutant EGFRvIII gene. Cell Growth Differ 1995 ; 6: 1251-1259.
29. Ponten J., Macintyre EH: Long term culture of normal and neoplastic human glia. Acta Pathol Microbiol Scand 1968 ; 74: 465-486.
30. Bepler G., Koehler A., Kiefer P., Havemann K., Beisenherz K., Jaques G.,, et al. Characterization of the state of differentiation of six newly established human non-small-cell lung cancer cell lines. Differentiation 1988 ; 37: 158-171.
31. Dekker S., Toussant W., Panayotou G., de Wit T., Visser P., Grosveld F.,, et al. Intracellularly expressed single-domain antibody against p15 matrix protein prevents the production of porcine retroviruses. J Virol 2003 ; 77: 12132-12139.
32. van der Linden R., de Geus B., Stok W., Bos W., van Wassenaar D., Verrips T.,, et al. Induction of immune responses and molecular cloning of the heavy chain antibody repertoire of Lama glama. J Immunol Methods 2000 ; 240: 185-195.
33. Hoogenboom HR, Griffiths AD, Johnson KS, Chiswell DJ, Hudson P., Winter G.: Multi-subunit proteins on the surface of filamentous phage: methodologies for displaying antibody (Fab) heavy and light chains. Nucleic Acids Res 1991 ; 19: 4133-4137.
34. Barbas CF III, Burton DR, Scott JK, Silverman GS: Phage Display: A Laboratory Manual. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press, 2001.
35. Woolven BP, Frenken LG, van der Logt P., Nicholls PJ: The structure of the llama heavy chain constant genes reveals a mechanism for heavy-chain antibody formation. Immunogenetics 1999 ; 50: 98-101.
36. Saitou N., Nei M.: The neighbor-joining method: a new method for reconstructing phylogenetic trees. Mol Biol Evol 1987 ; 4: 406-425.
37. Harmsen MM, Ruuls RC, Nijman IJ, Niewold TA, Frenken LG, de Geus B.: Llama heavy-chain V regions consist of at least four distinct subfamilies revealing novel sequence features. Mol Immunol 2000 ; 37: 579-590.
38. Jain RK: In Bicknell R, Lewis CE, Ferrara N (eds): Tumour Angiogenesis. Vascular and interstitial physiology of tumours: role in cancer detection & treatment. Oxford, UK: Oxford University Press, 1997: 45-59.
39. van der Linden RH, Frenken LG, de Geus B., Harmsen MM, Ruuls RC, Stok W.,, et al. Comparison of physical chemical properties of llama VHH antibody fragments and mouse monoclonal antibodies. Biochim Biophys Acta 1999 ; 1431: 37-46.
40. Cortez-Retamozo V., Lahoutte T., Caveliers V., Tchouate Gainkam LO, Hernot S., Packeu A.,, et al. 99mTc-labeled nanobodies: a new type of targeted probes for imaging antigen expression. Curr Radiopharm 2008 ; 1: 37-41.
41. Gainkam LO, Huang L., Caveliers V., Keyaerts M., Hernot S., Vaneycken I.,, et al. Comparison of the biodistribution and tumor targeting of two 99mTc-labeled anti-EGFR nanobodies in mice, using pinhole SPECT/Micro-CT. J Nucl Med 2008 ; 49: 788-795.
42. Huang L., Tchouate Gainkam LO, Caveliers V., Vanhove C., Keyaerts M., De Baetselier P.,, et al. SPECT imaging with (99m)Tc-labeled EGFR-specific nanobody for in vivo monitoring of EGFR expression. Mol Imaging Biol 2008 ; 10: 167-175.